ENLVNasdaqFinance ServicesFiscal year ends December 31
Enlivex Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 25, 2026
$0.21+0.00 (+1.17%)
Close on Oct 19, 2026
- Market cap
- $4.01M
- P/E (TTM)
- 0.0
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Mar 25, 2026 | Before market open | – | – | – |
Press releases
Announcements Enlivex filed with the SEC
THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED AS DIRECTED
EX-99.2 to Form 6-K
AS OF JUNE 30, 2026 AND DECEMBER 31, 2025
EX-99.1 to Form 6-K
Enlivex Announces Termination of Previously-Announced
EX-99.1 to Form 6-K
Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain
EX-99.1 to Form 6-K
Enlivex Announces $400,000,000 Private Placement
EX-99.1 to Form 6-K
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16;
EX-99.1 to Form 6-K
Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026
EX-99.1 to Form 6-K
Enlivex Treasury Portfolio Update: Listing
EX-99.1 to Form 6-K
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately
EX-99.1 to Form 6-K
Enlivex Treasury Portfolio Update: RAIN Holdings
EX-99.1 to Form 6-K
Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top
EX-99.1 to Form 6-K
Enlivex Announces Dosing Of First Patient In The United
EX-99.1 to Form 6-K
Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
EX-99.1 to Form 6-K
Ondo Global Markets Tokenizes Enlivex’s
EX-99.1 to Form 6-K
Enlivex Reports Full-Year 2025 Results: Profit (Net
EX-99.1 to Form 6-K
Enlivex Announces $21 Million Debt Financing,
EX-99.1 to Form 6-K
The Quality Longevity Company Powered by a Prediction Markets Treasury
EX-99.2 to Form 6-K
Quality Longevity Company Enlivex Receives Investigational
EX-99.1 to Form 6-K
PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON FEBRUARY 10, 2026
EX-99.1 to Form 6-K
AMENDED ARTICLES OF ASSOCIATION OF THE COMPANY
EX-99.1 to Form 6-K
PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON JANUARY 26, 2026
EX-99.1 to Form 6-K
PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON JANUARY 23, 2026
EX-99.1 to Form 6-K
PRESS RELEASE ISSUED BY ENLIVEX THERAPEUTICS LTD. ON JANUARY 7, 2026
EX-99.1 to Form 6-K
THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED AS DIRECTED
EX-99.2 to Form 6-K
PRESS RELEASE ISSUES BY ENLIVEX THERAPEUTICS LTD. ON DECEMBER 4, 2025
EX-99.1 to Form 6-K
Enlivex Announces Closing of Previously Announced
EX-99.1 to Form 6-K
This risk disclosure document is being delivered
EX-99.1 to Form 6-K
RAIN Treasury Strategy PubCo BUILT ON
EX-99.3 to Form 6-K
PRESS RELEASE ISSUES BY ENLIVEX THERAPEUTICS LTD. ON NOVEMBER 24, 2025
EX-99.1 to Form 6-K
ALLOCETRA FOR THE TREATMENT OF OSTEOARTHRITIS 8 | Nasdaq: ENLV
EX-99.2 to Form 6-K